Davita Healthcare Partners Inc: (NYSE: DVA)

$129.50

-0.66 (-0.51%)

Volume 303,136

Jun 18 04:02 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		128.76 - 130.45
	
		52wk Low - High
		88.03 - 131.33
	
		Previous Close
		130.16
	
		Avg. Volume
		551,788
	
		Industry
		MED-OUTP/HM CRE
	
		Market Cap
		13.77 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.41
	
		P/E (F1)
		17.28
	
		Current Year Est.
		7.53
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		178 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            17.28
                        
                            PEG Ratio
                            1.35
                        
                            Current Year Est.
                            7.53
                        
                            Current Quarter Estimate
                            1.86
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            6.51
                        
                            Expected Earnings Growth
                            12.83%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
DaVita Inc. is one of the largest providers of high-quality dialysis and related services for patients suffering from chronic kidney failure, also known as end stage renal disease. The company provides dialysis and ancillary services through a network of outpatient dialysis facilities.   
Full DVA Company Report

 Analyst Report on DVA

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
DVA Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	1.86	1.92	7.53	7.95
Number of Estimates	10	10	10	10
Low Estimate	1.78	1.84	7.32	7.32
High Estimate	1.99	2.03	7.71	NA
Year Ago EPS	1.49	1.50	6.25	7.53
EPS Growth	24.83%	28.20%	20.53%	5.56%

More DVA Estimates

Average Earnings Estimates for DVA

EPS Growth for DVA

Industry Analysis

Name	Symbol	Previous Close
DAVITA INC	DVA	130.16
ADDUS HOMECARE	ADUS	19.63
HEALTHSOUTH CP	HLS	29.55
LCA-VISION INC	LCAV	3.22
US PHYSICAL THR	USPH	30.16
AMSURG CORP	AMSG	36.21
BRAIN RESOURCE	BRRZY	0.00
CHINA CORD BLD	CO	2.87
LHC GROUP LLC	LHCG	22.25
QUEST DIAGNOSTC	DGX	62.59

Sector:Medical>> Industry:MED-OUTP/HM CRE

COMPARE TICKER vs. Its Peers

Zacks Commentary

DaVita and Myriad Join Forces

Jun 18, 2013

Balanced View on DaVita

Jun 10, 2013

DaVita's Stake in Columbian Co.

Jun 04, 2013

Fresenius Teams with ApolloMed

May 15, 2013

Weak 1Q Earnings for Gentiva

May 09, 2013

DaVita Reports Strong 1Q Earnings

May 08, 2013

Fresenius Earnings Lower Y/Y

May 01, 2013

Fresenius Teams with HCACO

Apr 09, 2013

More DVA Zacks Commentary

Financials

EPS TTM	6.51
Sales	8,186
Net Income	426
Price/Earnings	19.99
Price/Book	3.47
Price/Cash Flow	12.98
Price/Sales	1.50

More DVA Financials

News

DaVita (DVA) Approaches New Upside Target of $131.21 - Financial News Network Online - Pivot Alerts

Jun 17, 2013

DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration - Globenewswire

Jun 17, 2013

DaVita, Myriad RBM Announce Biomarker Research Collaboration - Benzinga

Jun 17, 2013

Bottom 5 Companies in the Health Care Services Industry with the Lowest Relative Performance (AMED, DVA, ESRX, LH, OCR) - Financial News Network Online - News Corner

Jun 14, 2013

DaVita (DVA) Could Fall Through $128.95 Support Level - Freshbrewedmedia

Jun 13, 2013

Watch for Shares of DaVita (DVA) to Approach Support at $128.95 - Financial News Network Online - Pivot Alerts

Jun 13, 2013

Amedisys is Among the Companies in the Health Care Services Industry with the Best Relative Performance (AMED, AIRM, DVA, HMSY, AH) - Financial News Network Online - News Corner

Jun 12, 2013

After Yesterday's Rally of 1.42% Shares Could Potentially Pullback - Comtex Smartrend(R)

Jun 11, 2013

See All News Stories on DVA

Broker Recommendations

Current ABR	1.75
ABR (Last Week)	1.75
# of recs in ABR	12
Average Target Price	130.44
Industry Rank by ABR	178 out of 265
Rank in Industry	5 out of 16

More DVA Broker Recommendations

Day Low - High	128.76 - 130.45
52wk Low - High	88.03 - 131.33
Previous Close	130.16
Avg. Volume	551,788
Industry	MED-OUTP/HM CRE
Market Cap	13.77 B
Div - Yield	0.00 - 0.00
Beta	0.41
P/E (F1)	17.28
Current Year Est.	7.53
Quarterly Earnings ESP	NA

P/E (F1)	17.28
PEG Ratio	1.35
Current Year Est.	7.53
Current Quarter Estimate	1.86
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	08-07-2013
EPS Last Year	6.51
Expected Earnings Growth	12.83%

Username: Password:

Remember me [?]

Davita Healthcare Partners Inc: (NYSE: DVA)

$129.50

-0.66 (-0.51%)

Volume 303,136

Jun 18 04:02 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-OUTP/HM CRE

Zacks Commentary

Financials

News

Broker Recommendations